跳至主要内容
临床试验/NCT01791452
NCT01791452Unknown不适用

Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study

Assy Nimer1 个研究点 分布在 1 个国家开始时间: 2013年2月15日最近更新:
适应症

试验速览

阶段
不适用
发起方
试验地点
1
主要终点
liver ultrasound, ultrasound Doppler of the common carotid artery, hepatic Fibroscan evaluation (transient elastography) for assessment of steatosis and fibrosis

研究概览

简要总结

Non-alcoholic fatty liver disease (NAFLD) is a world-wide problem with a global prevalence estimated at 1.5 billion people. It is characterised by significant diversity and phenotypic heterogeneity. Morbidity rates are estimated at 20% to 30% in Western adults, increasing to 90% in patients who are morbidly obese or diabetic. Risk factors in non-obese NAFLD patients are of especial practical and theoretical importance. Cholesterol Ester Storage Disease (CESD) is an autosomal recessive chronic disease of variable phenotype, caused by a deficiency in lysosomal acid lipase (LAL) and characterized by accumulation of fat in tissues and organs. Hepatic accumulation of fat in this disorder can cause hepatomegaly with varying degrees of damage varying from steatosis to fibrosis, elevated aminotransaminases, and isolated splenomegaly. Since the contribution of LAL deficiency to non-obese NAFLD is poorly understood, the investigators propose to evaluating the association between NAFLD and LAL deficiency in a prospective study in our population.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 18-80 years;
  • BMI 25-40;
  • Fatty liver disease (bright liver, hepatomegaly by ultrasound (Liver span > 15 cm mid clavicle line), splenomegaly (>13 cm) or both.

排除标准

  • Alcohol abuse>30 gm/day, or > 70 gram per week;
  • Soft drink abuse;
  • Drugs known to cause fatty liver;
  • Chronic hepatitis (B and C);
  • Biliary liver disease;
  • Autoimmune hepatitis;
  • Genetic/Metabolic liver disease (Wilson, alpha-1 antitrypsin, CF);
  • Failure to give informed consent

结局指标

主要结局

liver ultrasound, ultrasound Doppler of the common carotid artery, hepatic Fibroscan evaluation (transient elastography) for assessment of steatosis and fibrosis

时间窗: year

次要结局

未报告次要终点

研究者

发起方
Assy Nimer
申办方类型
Other Gov
责任方
Sponsor Investigator
主要研究者

Assy Nimer

MD

Ziv Hospital

研究点 (1)

Loading locations...

相似试验